Osteomyelitis in Emergency Medicine

Back

Background

Osteomyelitis is an acute or chronic inflammatory process of the bone and its structures secondary to infection with pyogenic organisms.

Pathophysiology

Osteomyelitis may be localized or it may spread through the periosteum, cortex, marrow, and cancellous tissue. The bacterial pathogen varies on the basis of the patient's age and the mechanism of infection.

The following are the 2 primary categories of acute osteomyelitis: hematogenous osteomyelitis and direct or contiguous inoculation osteomyelitis.

Hematogenous osteomyelitis is an infection caused by bacterial seeding from the blood. Acute hematogenous osteomyelitis is characterized by an acute infection of the bone caused by the seeding of the bacteria within the bone from a remote source. This condition primarily occurs in children. The most common site is the rapidly growing and highly vascular metaphysis of growing bones. The apparent slowing or sludging of blood flow as the vessels make sharp angles at the distal metaphysis predisposes the vessels to thrombosis and the bone itself to localized necrosis and bacterial seeding.

Vertebral osteomyelitis at any age is most often a secondary complication of a remote infection with hematogenous seeding. In approximately one half of vertebral osteomyelitis cases, a source can be identified such as urinary tract or skin, and approximately one third may be diagnosed with endocarditis.[1] Acute hematogenous osteomyelitis, despite its name, may have a slow clinical development and insidious onset.

Direct or contiguous inoculation osteomyelitis is caused by direct contact of the tissue and bacteria during trauma or surgery. Direct inoculation (contiguous-focus) osteomyelitis is an infection in the bone secondary to the inoculation of organisms from direct trauma, spread from a contiguous focus of infection, or sepsis after a surgical procedure. Clinical manifestations of direct inoculation osteomyelitis are more localized than those of hematogenous osteomyelitis and tend to involve multiple organisms.

Additional categories include chronic osteomyelitis and osteomyelitis secondary to peripheral vascular disease. Chronic osteomyelitis persists or recurs, regardless of its initial cause and/or mechanism and despite aggressive intervention. Although listed as an etiology, peripheral vascular disease is actually a predisposing factor rather than a true cause of infection.

Disease states known to predispose patients to osteomyelitis include diabetes mellitus,[2] sickle cell disease, acquired immune deficiency syndrome (AIDS), intravenous (IV) drug abuse, alcoholism, chronic steroid use, immunosuppression, and chronic joint disease. In addition, the presence of a prosthetic orthopedic device is an independent risk factor, as is any recent orthopedic surgery or open fracture.

For the radiologic perspective, see Osteomyelitis, Acute Pyogenic and Osteomyelitis, Chronic.

Epidemiology

Frequency

United States

The overall prevalence is 1 case per 5,000 children. Neonatal prevalence is approximately 1 case per 1,000. The annual incidence in patients with sickle cell anemia is approximately 0.36%. The prevalence of osteomyelitis after foot puncture (as is seen in the image below) may be as high as 16% (30-40% in patients with diabetes). The incidence of vertebral osteomyelitis is approximately 2.4 cases per 100,000 population.[1]



View Image

Osteomyelitis of diabetic foot. Photography by David Effron MD, FACEP.

International

The overall incidence is higher in developing countries.

Mortality/Morbidity

Morbidity can be significant and can include localized spread of infection to associated soft tissues or joints; evolution to chronic infection, with pain and disability; amputation of the involved extremity; generalized infection; or sepsis. As many as 10-15% of patients with vertebral osteomyelitis develop neurologic findings or frank spinal-cord compression. As many as 30% of pediatric patients with long-bone osteomyelitis may develop deep venous thrombosis (DVT). The development of DVT may also be a marker for disseminated infection.[3, 4] Vascular complications appear to be more common with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) than was previously recognized.[5]

Mortality rates are low, unless associated sepsis or an underlying serious medical condition is present.

Race

No increased incidence of osteomyelitis is noted based on race.

Sex

Males are at increased relative risk, which increases through childhood, peaking in adolescence and falling to a low ratio in adults.[6]

Age

In general, osteomyelitis has a bimodal age distribution. Acute hematogenous osteomyelitis is primarily a disease in children. Direct trauma and contiguous focus osteomyelitis are more common among adults and adolescents than in children. Vertebral osteomyelitis is more common in persons older than 45 years.

Prognosis

The prognosis for osteomyelitis varies but is markedly improved with timely diagnosis and aggressive therapeutic intervention.

History

Hematogenous osteomyelitis usually presents with a slow insidious progression of symptoms. Direct osteomyelitis generally is more localized, with prominent signs and symptoms. General symptoms of osteomyelitis are dicussed below.

The following are general symptoms of hematogenous long-bone osteomyelitis:

The following are general symptoms of hematogenous vertebral osteomyelitis:

The following are general symptoms of chronic osteomyelitis:

Physical

Findings at physical examination may include the following:

Causes

Note that responsible pathogens may be isolated in only 35%-40% of infections.

Causes of acute hematogenous osteomyelitis are as follows (note increasing reports of other pathogens in bone and joint infections including community-associated methicillin-resistant Staphylococcus aureus [MRSA],[8] Kingella kingae,[9] and others):

Causes of direct osteomyelitis are as follows:

Also see Medscape's Infectious Diseases Resource Center.

Complications

Complications of osteomyelitis may include the following:

Approach Considerations

The studies below are indicated in patients with osteomyelitis.

The Infectious Diseases Society of America (IDSA) issued new guidelines on vertebral osteomyelitis in 2015.[10, 11]

Laboratory Studies

The studies below are indicated in patients with osteomyelitis.

CBC count

The WBC count may be elevated, but it is frequently normal.

A leftward shift is common with increased polymorphonuclear leukocyte counts.

C-reactive protein

The C-reactive protein level is usually elevated and nonspecific; this study may be more useful than the erythrocyte sedimentation rate (ESR) because it reveals elevation earlier.

ESR/CRP

The ESR is usually elevated (90%); however, this finding is clinically nonspecific.

CRP and ESR have limited roles in the setting of chronic osteomyelitis and are often normal.

Elevated ESR and CRP may suggest vertebral osteomyelitis.[10, 11]

Procalcitonin

Procalcitonin elevation: This can potentially be useful in diagnosis because it is relatively specific; however, it lacks sensitivity.[12]

Culture

Superficial wound or sinus tract cultures often do not correlate with the bacteria that is causing osteomyelitis and have limited use. Blood culture results are positive in approximately 50% of patients with hematogenous osteomyelitis. However, a positive blood culture may preclude the need for further invasive procedures to isolate the organism. Bone cultures from biopsy or aspiration have a diagnostic yield of approximately 77% across all studies.[1]

Imaging Studies

Radiography

Radiographic evidence of acute osteomyelitis is first suggested by overlying soft-tissue edema at 3-5 days after infection. Examples of radiographic evidence of osteomyelitis are presented in the images below.



View Image

Osteomyelitis of the elbow. Photography by David Effron MD, FACEP.



View Image

Osteomyelitis of index finger metacarpal head secondary to clenched fist injury. Photography by David Effron MD, FACEP.



View Image

Osteomyelitis of the great toe. Photography by David Effron MD, FACEP.



View Image

Osteomyelitis of T10 secondary to streptococcal disease. Photography by David Effron MD, FACEP.



View Image

Osteomyelitis. Radiography of diabetic foot showing osteomyelitis with gas. Photography by David Effron MD, FACEP.

Bony changes are not evident for 14-21 days and initially manifest as periosteal elevation followed by cortical or medullary lucencies. By 28 days, 90% of patients demonstrate some abnormality.

Approximately 40-50% focal bone loss is necessary to cause detectable lucency on plain films.

In patients in whom TB is of concern, chest radiography may demonstrate lesions characteristic of TB.

Plain radiographs of the spine are not sensitive for early diagnosis of vertebral osteomyelitis.[10, 11]

MRI

The MRI is effective in the early detection and surgical localization of osteomyelitis.[13, 14]

Studies have shown its superiority compared with plain radiography, CT, and radionuclide scanning and is considered to be the imaging of choice.

Sensitivity ranges from 90-100%.

Patients with elevated ESR and CRP levels should undergo MRI to distinguish infection from disc herniation or other structural cause of back pain.[10, 11]

Positron emission tomographic scanning

Positron emission tomographic (PET) scanning has accuracy similar to MRI.

Radionuclide bone scanning

Three phase bone scan, gallium scan and tagged WBC scan are considerations in patients who are unable to have MRI imaging. A three phase bone scan has high sensitivity and specificity in adults with normal findings on radiograph. Specificity is dramatically decreased in the setting of previous surgery or traumatized bone.

In special circumstances, additional information can be obtained from further scanning with leukocytes labeled with gallium 67 and/or indium 111.

CT scanning

CT scans can depict abnormal calcification, ossification, and intracortical abnormalities.

It is not recommended for routine use for diagnosing osteomyelitis but is often the imaging of choice when MRI is not available

Ultrasonography

This simple and inexpensive technique has shown promise, particularly in children with acute osteomyelitis.

Ultrasonography may demonstrate changes as early as 1-2 days after onset of symptoms.

Abnormalities include soft tissue abscess or fluid collection and periosteal elevation.

Ultrasonography allows for ultrasound-guided aspiration.

It does not allow for evaluation of bone cortex.

Procedures

The probe to bone (PTB) test may be a useful rapid adjunct in the evaluation of the diabetic foot. The procedure involves inserting a blunt probe into the suspected ulceration on the plantar surface of the foot. A "click" (solid or gritty end point) indicates a positive finding. Note that location of the ulcer and the performer’s expertise may affect reliability.[15] . A positive PTB test finding in a high-risk patient indicates a high probability of osteomyelitis. A negative PTB test result in a low-risk patient indicates a low probability of osteomyelitis.[16]

Emergency Department Care

Osteomyelitis rarely requires emergent stabilization or resuscitation. The primary challenge for ED physicians is considering the appropriate diagnosis in the face of subtle signs or symptoms.

Treatment for osteomyelitis involves the following:

Select the appropriate antibiotics using direct culture results in samples from the infected site, whenever possible. Empiric therapy is usually delayed until culture results can be obtained to better target definitive future antibiotic coverage. Empiric therapy is often initiated on the basis of the patient's age and the clinical presentation. Therapy should always include coverage for S aureus and consideration of CA-MRSA. Further surgical management may involve removal of the nidus of infection, implantation of antibiotic beads or pumps, hyperbaric oxygen therapy,[17] or other modalities.

Diagnosis requires 2 of the 4 following criteria:

Consultations

Order an orthopedics, general surgery, or infectious disease consultation, as needed. Patients with diabetic foot osteomyelitis are best cared for by a multidisciplinary team.[18]

Prevention

Acute hematogenous osteomyelitis can potentially be avoided by preventing bacterial seeding of bone from a remote site. This involves the appropriate diagnosis and treatment of primary bacterial infections.

Direct inoculation osteomyelitis can best be prevented with appropriate wound management and consideration of prophylactic antibiotic use at the time of injury.

Long-Term Monitoring

Patients with vertebral osteomyelitis whose pain resolves after antibiotic treatment or surgery generally do not require repeat MRI.[10, 11]

Medication Summary

The primary treatment for osteomyelitis is parenteral antibiotics that penetrate bone and joint cavities. Treatment is required for at least 4-6 weeks. After intravenous antibiotics are initiated on an inpatient basis, therapy may be continued with intravenous or oral antibiotics, depending on the type and location of the infection, on an outpatient basis.

Below are recommendations for the initiation of empiric antibiotic treatment based on the age of the patient and mechanism of infection.

With hematogenous osteomyelitis (newborn to adult), the infectious agents include S aureus, Enterobacteriaceae organisms, group A and B Streptococcus species, and H influenzae. Primary treatment is a combination of penicillinase-resistant synthetic penicillin and a third-generation cephalosporin. Alternate therapy is vancomycin or clindamycin and a third-generation cephalosporin, particularly if methicillin-resistant S aureus (MRSA) is considered likely. Linezolid is also used in these circumstances.[19, 20] In addition to these above-mentioned antibacterials, ciprofloxacin and rifampin may be an appropriate combination therapy for adult patients. If evidence of infection with gram-negative bacilli is observed, include a third-generation cephalosporin.

While data on efficacy are limited, additional choices for gram-positive coverage in adults may also include daptomycin, telavancin, or ceftaroline.[21]

In patients with sickle cell anemia and osteomyelitis, the primary bacterial causes are S aureus and Salmonellae species. Thus, the primary choice for treatment is a fluoroquinolone antibiotic (not in children). A third-generation cephalosporin (eg, ceftriaxone) is an alternative choice.

When a nail puncture occurs through an athletic shoe, the infecting agents may include S aureus and Pseudomonas aeruginosa. The primary antibiotics in this scenario include ceftazidime or cefepime. Ciprofloxacin is an alternative treatment.

For patients with osteomyelitis due to trauma, the infecting agents include S aureus, coliform bacilli, and Pseudomonas aeruginosa. Primary antibiotics include nafcillin and ciprofloxacin. Alternatives include vancomycin and a third-generation cephalosporin with antipseudomonal activity.

In patients in whom tuberculosis is of concern as the etiology of a musculoskeletal infection, the choice of antibiotic is generally the same as for pulmonary infection.

Vertebral osteomyelitis

According to 2015 guidelines on vertebral osteomyelitis issued by the IDSA, unless patients are septic or have neurologic compromise, empiric antimicrobial therapy should be withheld until the microbiologic diagnosis is confirmed.[10, 11]

Most patients with S aureus bloodstream infection within the preceding 3 months and compatible spine MRI changes may be treated empirically without disc space aspiration.

Treatment usually includes intravenous antibiotics for 6 weeks based on the results of culture and in vitro susceptibility testing.

Nafcillin (Nafcil, Unipen)

Clinical Context:  Initial therapy for suspected penicillin G–resistant streptococcal or staphylococcal infections. Use parenteral therapy initially in severe infections. Change to oral therapy as condition warrants. Because of thrombophlebitis, particularly in elderly patients, administer parenterally for only the short term (1-2 d). Change to PO route as clinically indicated. Note: Administer in combination with a third-generation cephalosporin to treat osteomyelitis. Do not admix with aminoglycosides for IV administration.

Ceftriaxone (Rocephin)

Clinical Context:  Third-generation cephalosporin with broad-spectrum gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms; arrests bacterial growth by binding to one or more penicillin-binding proteins. Note: Administer with a penicillinase-resistant synthetic penicillin, when treating osteomyelitis.

Cefazolin (Ancef)

Clinical Context:  First-generation semisynthetic cephalosporin that arrests bacterial cell wall synthesis, inhibiting bacterial growth; primarily active against skin flora, including S aureus; typically used alone for skin and skin-structure coverage.

Ciprofloxacin (Cipro)

Clinical Context:  Fluoroquinolone with activity against pseudomonads, streptococci, MRSA, Staphylococcus epidermidis, and most gram-negative organisms, but no activity against anaerobes. Inhibits bacterial DNA synthesis and, consequently, growth. Continue treatment for at least 2 d (typical treatment, 7-14 d) after signs and symptoms disappear.

Ceftazidime (Fortaz, Ceptaz)

Clinical Context:  Third-generation cephalosporin with broad-spectrum gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms; arrests bacterial growth by binding to one or more penicillin-binding proteins.

Clindamycin (Cleocin)

Clinical Context:  Lincosamide for the treatment of serious skin and soft-tissue staphylococcal infections; also effective against aerobic and anaerobic streptococci (except enterococci); inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, arresting RNA-dependent protein synthesis.

Vancomycin (Vancocin)

Clinical Context:  Potent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in the treatment of septicemia and skin structure infections. Indicated for patients who can not receive or have failed to respond to penicillins and cephalosporins or have infections with resistant staphylococci. For abdominal penetrating injuries, it is combined with an agent active against enteric flora and/or anaerobes.

To avoid toxicity, current recommendation is to assay vancomycin trough levels after third dose drawn 0.5 h prior to next dosing. Use creatinine clearance to adjust dose in patients with renal impairment.

Used in conjunction with gentamicin for prophylaxis in penicillin-allergic patients undergoing gastrointestinal or genitourinary procedures.

Linezolid (Zyvox)

Clinical Context:  Prevents formation of functional 70S initiation complex, which is essential for bacterial translation process. Bacteriostatic against staphylococci.

The FDA warns against the concurrent use of linezolid with serotonergic psychiatric drugs, unless indicated for life-threatening or urgent conditions. Linezolid may increase serotonin CNS levels as a result of MAO-A inhibition, increasing the risk of serotonin syndrome.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Rifampin

Clinical Context:  For use in combination with at least one other antituberculous drug. Inhibits DNA-dependent bacterial RNA polymerase but not mammalian RNA polymerase. Cross-resistance may occur.

Treat for 6-9 months or until 6 months have elapsed from conversion to sputum culture negativity.

What is osteomyelitis?What is the pathophysiology of osteomyelitis?What is the prevalence of osteomyelitis in the US?What is the global prevalence of osteomyelitis?What are the morbidity and mortality associated with osteomyelitis?What are the racial predilections of osteomyelitis?What are the sexual predilections of osteomyelitis?Which age groups have the highest prevalence of osteomyelitis?What is the prognosis of osteomyelitis?What are the signs and symptoms of osteomyelitis?Which physical findings are characteristic of osteomyelitis?What causes osteomyelitis?What are the possible complications of osteomyelitis?What are the differential diagnoses for Osteomyelitis in Emergency Medicine?Which organization has issued guidelines on the diagnosis and treatment of osteomyelitis?Which findings on CBC count are characteristic of osteomyelitis?Which findings of C-reactive protein level is characteristic of osteomyelitis?What is the role of ESR in the workup of osteomyelitis?What is the role of procalcitonin in the workup of osteomyelitis?What is the role of blood culture in the workup of osteomyelitis?What is the role of radiography in the workup of osteomyelitis?What is the role of MRI in the workup of osteomyelitis?What is the roe of PET scans in the workup of osteomyelitis?What is the role of nuclear imaging in the workup of osteomyelitis?What is the role of CT scanning in the workup of osteomyelitis?What is the role of ultrasonography in the workup of osteomyelitis?What is the role of a probe to bone (PTB) test in the workup of osteomyelitis?How is osteomyelitis treated in the emergency department (ED)?What are the diagnostic criteria for osteomyelitis?Which specialist consultations are beneficial to patients with osteomyelitis?How is osteomyelitis prevented?What is included in the long-term monitoring of osteomyelitis?What is the role of medications in the treatment of osteomyelitis?Which medications in the drug class Antibiotic, Miscellaneous are used in the treatment of Osteomyelitis in Emergency Medicine?Which medications in the drug class Antibiotics are used in the treatment of Osteomyelitis in Emergency Medicine?

Author

Randall W King, MD, FACEP, Assistant Clinical Professor of Emergency Medicine, University of Toledo College of Medicine; Director, Emergency Medicine Residency Program, Department of Emergency Medicine, Chief Medical Information Officer, Chief of Staff Elect, Mercy St Vincent Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

David Johnson, MD, Assistant Clinical Professor, Department of Surgery, University of Toledo College of Medicine; Chairman, Department of Emergency Services, St Vincent's Mercy Medical Center, Toledo

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Eric L Weiss, MD, DTM&H, Medical Director, Office of Service Continuity and Disaster Planning, Fellowship Director, Stanford University Medical Center Disaster Medicine Fellowship, Chairman, SUMC and LPCH Bioterrorism and Emergency Preparedness Task Force, Clinical Associate Professor, Department of Surgery (Emergency Medicine), Stanford University Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Jeter (Jay) Pritchard Taylor, III, MD, Assistant Professor, Department of Surgery, University of South Carolina School of Medicine; Attending Physician, Clinical Instructor, Compliance Officer, Department of Emergency Medicine, Palmetto Richland Hospital

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Employed contractor - Chief Editor for Medscape.

Additional Contributors

Dana A Stearns, MD, Assistant Director of Undergraduate Education, Department of Emergency Medicine, Massachusetts General Hospital; Associate Director, Undergraduate Clerkship in Surgery, Massachusetts General Hospital/Harvard Medical School; Assistant Professor of Surgery, Harvard Medical School

Disclosure: Nothing to disclose.

References

  1. Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010 Mar 18. 362(11):1022-9. [View Abstract]
  2. [Guideline] Schweitzer ME, Daffner RH, Weissman BN, et al. Expert Panel on Musculoskeletal Imaging. ACR Appropriateness Criteria® suspected osteomyelitis in patients with diabetes mellitus. [online publication]. Reston (VA): American College of Radiology (ACR); 2008.
  3. Crary SE, Buchanan GR, Drake CE, Journeycake JM. Venous thrombosis and thromboembolism in children with osteomyelitis. J Pediatr. 2006 Oct. 149(4):537-41. [View Abstract]
  4. Schaub RL, Rodkey ML. Deep vein thrombosis and septic pulmonary emboli with MRSA osteomyelitis in a pediatric patient. Pediatr Emerg Care. 2012 Sep. 28(9):911-2. [View Abstract]
  5. Kaplan SL. Osteomyelitis in children. Infect Dis Clin North Am. 2005 Dec. 19(4):787-97, vii. [View Abstract]
  6. Chihara S, Segreti J. Osteomyelitis. Dis Mon. 2010 Jan. 56(1):5-31. [View Abstract]
  7. Germain ML, Krenzer KA, Hasley BP, Varman M. 11-month-old child refuses to sit up. Pediatr Ann. 2008 May. 37(5):290-3. [View Abstract]
  8. Saavedra-Lozano J, Mejias A, Ahmad N, et al. Changing trends in acute osteomyelitis in children: impact of methicillin-resistant Staphylococcus aureus infections. J Pediatr Orthop. 2008 Jul-Aug. 28(5):569-75. [View Abstract]
  9. Kiang KM, Ogunmodede F, Juni BA, et al. Outbreak of osteomyelitis/septic arthritis caused by Kingella kingae among child care center attendees. Pediatrics. 2005 Aug. 116(2):e206-13. [View Abstract]
  10. Barclay L. First US guidelines for vertebral osteomyelitis released. Medscape Medical News. WebMD Inc. Available at http://www.medscape.com/viewarticle/848897. July 31, 2015; Accessed: September 29, 2015.
  11. [Guideline] Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adultsa. Clin Infect Dis. 2015 Sep 15. 61 (6):e26-46. [View Abstract]
  12. Shen CJ, Wu MS, Lin KH, Lin WL, Chen HC, Wu JY, et al. The use of procalcitonin in the diagnosis of bone and joint infection: a systemic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2013 Jun. 32(6):807-14. [View Abstract]
  13. Aloui N, Nessib N, Jalel C, et al. [Acute osteomyelitis in children: early MRI diagnosis]. J Radiol. 2004 Apr. 85(4 Pt 1):403-8. [View Abstract]
  14. Pruthi S, Thapa MM. Infectious and inflammatory disorders. Radiol Clin North Am. 2009 Nov. 47(6):911-26.
  15. Álvaro-Afonso FJ, Lázaro-Martínez JL, Aragón-Sánchez FJ, García-Morales E, Carabantes-Alarcón D, Molines-Barroso RJ. Does the location of the ulcer affect the interpretation of the probe-to-bone test in the diagnosis of osteomyelitis in diabetic foot ulcers?. Diabet Med. 2014 Jan. 31 (1):112-3. [View Abstract]
  16. Lam K, van Asten SA, Nguyen T, La Fontaine J, Lavery LA. Diagnostic Accuracy of Probe to Bone to Detect Osteomyelitis in the Diabetic Foot: A Systematic Review. Clin Infect Dis. 2016 Oct 1. 63 (7):944-8. [View Abstract]
  17. Kindwall EP. Uses of hyperbaric oxygen therapy in the 1990s. Cleve Clin J Med. 1992 Sep-Oct. 59(5):517-28. [View Abstract]
  18. Byren I, Peters EJ, Hoey C, Berendt A, Lipsky BA. Pharmacotherapy of diabetic foot osteomyelitis. Expert Opin Pharmacother. 2009 Dec. 10(18):3033-47. [View Abstract]
  19. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J. 2003 Aug. 22 (8):677-86. [View Abstract]
  20. Kimberlin DW, Brady MT, Jackson MA, Long SS. Staphylococcal infections. American Academy of Pediatrics Red Book. 30th. 2015. 715.
  21. Moenster RP, Linneman TW, Call WB, Kay CL, McEvoy TA, Sanders JL. The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults. J Clin Pharm Ther. 2013 Apr. 38 (2):89-96. [View Abstract]
  22. Asmar BI. Osteomyelitis in the neonate. Infect Dis Clin North Am. 1992 Mar. 6(1):117-32. [View Abstract]
  23. Bamberger DM. Diagnosis and treatment of osteomyelitis. Compr Ther. 2000 Summer. 26(2):89-95. [View Abstract]
  24. Bocchini CE, Hulten KG, Mason EO Jr, Gonzalez BE, Hammerman WA, Kaplan SL. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics. 2006 Feb. 117(2):433-40. [View Abstract]
  25. Cheatle MD. The effect of chronic orthopedic infection on quality of life. Orthop Clin North Am. 1991 Jul. 22(3):539-47. [View Abstract]
  26. Chisholm CD, Schlesser JF. Plantar puncture wounds: controversies and treatment recommendations. Ann Emerg Med. 1989 Dec. 18(12):1352-7. [View Abstract]
  27. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin Infect Dis. 2008 Aug 15. 47(4):519-27. [View Abstract]
  28. Euba G, Murillo O, Fernández-Sabé N, Mascaró J, Cabo J, Pérez A, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother. 2009 Jun. 53(6):2672-6. [View Abstract]
  29. Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis. 2005 Mar 1. 40(5):695-703. [View Abstract]
  30. Gelfand MS, Cleveland KO. Vancomycin therapy and the progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis. South Med J. 2004 Jun. 97(6):593-7. [View Abstract]
  31. Goergens ED, McEvoy A, Watson M, Barrett IR. Acute osteomyelitis and septic arthritis in children. J Paediatr Child Health. 2005 Jan-Feb. 41(1-2):59-62. [View Abstract]
  32. Gosselin RA, Roberts I, Gillespie WJ. Antibiotics for preventing infection in open limb fractures. Cochrane Database Syst Rev. 2004. CD003764. [View Abstract]
  33. Harwood PJ, Talbot C, Dimoutsos M, et al. Early experience with linezolid for infections in orthopaedics. Injury. 2006 Sep. 37(9):818-26. [View Abstract]
  34. Henry NK, Rouse MS, Whitesell AL, McConnell ME, Wilson WR. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med. 1987 Apr 27. 82(4A):73-5. [View Abstract]
  35. Hollmig ST, Copley LA, Browne RH, Grande LM, Wilson PL. Deep venous thrombosis associated with osteomyelitis in children. J Bone Joint Surg Am. 2007 Jul. 89(7):1517-23. [View Abstract]
  36. Hsu LY, Koh TH, Tan TY. Emergence of community-associated methicillin-resistant Staphylococcus aureus in Singapore: a further six cases. Singapore Med J. 2006 Jan. 47(1):20-6. [View Abstract]
  37. Kabak S, Tuncel M, Halici M, Tutus A, Baktir A, Yildirim C. Role of trauma on acute haematogenic osteomyelitis aetiology. Eur J Emerg Med. 1999 Sep. 6(3):219-22. [View Abstract]
  38. Kaiser S, Jorulf H, Hirsch G. Clinical value of imaging techniques in childhood osteomyelitis. Acta Radiol. 1998 Sep. 39(5):523-31. [View Abstract]
  39. Karamanis EM, Matthaiou DK, Moraitis LI, Falagas ME. Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials. Spine (Phila Pa 1976). 2008 May 1. 33(10):E297-304. [View Abstract]
  40. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011 Feb 1. 52(3):285-92. [View Abstract]
  41. Mandracchia VJ, Sanders SM, Jaeger AJ, Nickles WA. Management of osteomyelitis. Clin Podiatr Med Surg. 2004 Jul. 21(3):335-51, vi. [View Abstract]
  42. Martinez-Aguilar G, Hammerman WA, Mason EO. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003 Jul. 22(7):593-8. [View Abstract]
  43. Martínez-Aguilar G, Avalos-Mishaan A, Hulten K, Hammerman W, Mason EO Jr, Kaplan SL. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J. 2004 Aug. 23(8):701-6. [View Abstract]
  44. Moumile K, Merckx J, Glorion C, Pouliquen JC, Berche P, Ferroni A. Bacterial aetiology of acute osteoarticular infections in children. Acta Paediatr. 2005 Apr. 94(4):419-22. [View Abstract]
  45. Nguyen S, Pasquet A, Legout L, Beltrand E, Dubreuil L, Migaud H. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect. 2009 Dec. 15(12):1163-9. [View Abstract]
  46. Nicolau DP, Nie L, Tessier PR, Kourea HP, Nightingale CH. Prophylaxis of acute osteomyelitis with absorbable ofloxacin-impregnated beads. Antimicrob Agents Chemother. 1998 Apr. 42(4):840-2. [View Abstract]
  47. Perron AD, Brady WJ, Miller MD. Orthopedic pitfalls in the ED: osteomyelitis. Am J Emerg Med. 2003 Jan. 21(1):61-7. [View Abstract]
  48. Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res. 2004 Oct. 67-71. [View Abstract]
  49. Rasmont Q, Yombi JC, Van der Linden D, Docquier PL. Osteoarticular infections in Belgian children: a survey of clinical, biological, radiological and microbiological data. Acta Orthop Belg. 2008 Jun. 74(3):374-85. [View Abstract]
  50. Restrepo CS, Lemos DF, Gordillo H, et al. Imaging findings in musculoskeletal complications of AIDS. Radiographics. 2004 Jul-Aug. 24(4):1029-49. [View Abstract]
  51. Roberts DE. Femoral osteomyelitis after tooth extraction. Am J Orthop (Belle Mead NJ). 1998 Sep. 27(9):624-6. [View Abstract]
  52. Sadat-Ali M. The status of acute osteomyelitis in sickle cell disease. A 15-year review. Int Surg. 1998 Jan-Mar. 83(1):84-7. [View Abstract]
  53. Sammak B, Abd El Bagi M, Al Shahed M, et al. Osteomyelitis: a review of currently used imaging techniques. Eur Radiol. 1999. 9(5):894-900. [View Abstract]
  54. Schauwecker DS. The scintigraphic diagnosis of osteomyelitis. AJR Am J Roentgenol. 1992 Jan. 158(1):9-18. [View Abstract]
  55. Segev S, Yaniv I, Haverstock D, Reinhart H. Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. Clin Infect Dis. 1999 Feb. 28(2):299-308. [View Abstract]
  56. Seligson D, Klemm K. Adult posttraumatic osteomyelitis of the tibial diaphysis of the tibial shaft. Clin Orthop Relat Res. 1999 Mar. 30-6. [View Abstract]
  57. Shedek BK, Nilles EJ. Community-associated methicillin-resistant Staphylococcus aureus pyomyositis complicated by compartment syndrome in an immunocompetent young woman. Am J Emerg Med. 2008 Jul. 26(6):737.e3-4. [View Abstract]
  58. Shih HN, Shih LY, Wong YC. Diagnosis and treatment of subacute osteomyelitis. J Trauma. 2005 Jan. 58(1):83-7. [View Abstract]
  59. Sonnen GM, Henry NK. Pediatric bone and joint infections. Diagnosis and antimicrobial management. Pediatr Clin North Am. 1996 Aug. 43(4):933-47. [View Abstract]
  60. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012 Feb 1. 54(3):393-407. [View Abstract]
  61. Steer AC, Carapetis JR. Acute hematogenous osteomyelitis in children: recognition and management. Paediatr Drugs. 2004. 6(6):333-46. [View Abstract]
  62. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis. 2001 Oct. 1(3):175-88. [View Abstract]
  63. Trobs R, Moritz R, Buhligen U, et al. Changing pattern of osteomyelitis in infants and children. Pediatr Surg Int. 1999 Jul. 15(5-6):363-72. [View Abstract]
  64. Tsukayama DT. Pathophysiology of posttraumatic osteomyelitis. Clin Orthop Relat Res. 1999 Mar. 22-9. [View Abstract]
  65. US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox®) is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm. Accessed: July 27, 2011.
  66. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004 Aug. 29(4):351-7. [View Abstract]
  67. Waagner DC. Musculoskeletal infections in adolescents. Adolesc Med. 2000 Jun. 11(2):375-400. [View Abstract]
  68. Walenkamp GH, Kleijn LL, de Leeuw M. Osteomyelitis treated with gentamicin-PMMA beads: 100 patients followed for 1-12 years. Acta Orthop Scand. 1998 Oct. 69(5):518-22. [View Abstract]
  69. Walters HL, Measley R. Two cases of Pseudomonas aeruginosa epidural abscesses and cervical osteomyelitis after dental extractions. Spine (Phila Pa 1976). 2008 Apr 20. 33(9):E293-6. [View Abstract]
  70. Yun HC, Branstetter JG, Murray CK. Osteomyelitis in military personnel wounded in Iraq and Afghanistan. J Trauma. 2008 Feb. 64(2 Suppl):S163-8; discussion S168. [View Abstract]
  71. Zalavras CG, Patzakis MJ, Holtom P. Local antibiotic therapy in the treatment of open fractures and osteomyelitis. Clin Orthop Relat Res. 2004 Oct. 86-93. [View Abstract]

Osteomyelitis of diabetic foot. Photography by David Effron MD, FACEP.

Osteomyelitis of the elbow. Photography by David Effron MD, FACEP.

Osteomyelitis of index finger metacarpal head secondary to clenched fist injury. Photography by David Effron MD, FACEP.

Osteomyelitis of the great toe. Photography by David Effron MD, FACEP.

Osteomyelitis of T10 secondary to streptococcal disease. Photography by David Effron MD, FACEP.

Osteomyelitis. Radiography of diabetic foot showing osteomyelitis with gas. Photography by David Effron MD, FACEP.

Osteomyelitis of the elbow. Photography by David Effron MD, FACEP.

Osteomyelitis of index finger metacarpal head secondary to clenched fist injury. Photography by David Effron MD, FACEP.

Osteomyelitis of index finger metacarpal head secondary to clenched fist injury. Photography by David Effron MD, FACEP.

Osteomyelitis of the great toe. Photography by David Effron MD, FACEP.

Osteomyelitis of T10 secondary to streptococcal disease. Photography by David Effron MD, FACEP.

Osteomyelitis of diabetic foot. Photography by David Effron MD, FACEP.

Osteomyelitis. Radiography of diabetic foot showing osteomyelitis with gas. Photography by David Effron MD, FACEP.